The outbreak of coronavirus disease 2019 (COVID-19) remains a severe public health emergency of international concern. Over the past months, several investigations have suggested an association between the COVID-19 pathogenesis and a pro-coagulant pattern that seems to be implicated in a higher risk of both arterial and venous thrombotic events [1-7]. In this regard, acute pulmonary embolism (PE) has emerged as a potential severe complication of the infection and both American and European consensus statement have suggested general recommendations to deal with these clinical events [8-11].
